A
new research report by Transparency Market Research offers a
comprehensive evaluation of the global Niclosamide
Market. The
study, titled “Niclosamide
Market - Global Industry Analysis, Size, Share, Growth, Trends, and
Forecast 2017 - 2025”,
is available for sale on the firm’s website.
Niclosamide,
belonging to the salicylanilide anti-helminthic class of medicines,
is a dose-dependent low micro-molar inhibitor of the human
rhinovirus. This prescription drug is used in the treatment of
tapeworm infections. It works by eliminating the tapeworms. The
infection of Taenia solium (called taeniasis/cysticercosis) occurs
via contaminated food or water and creates major health problems. The
T. solium infected over 50 million individuals worldwide in 2015.
This infection causes epilepsy of liver and as per the World Health
Organization, more than 80% of the patients affected by epilepsy
lived in low and middle income countries. In 2015, China, India,
Brazil, Mexico, and parts of Africa experienced an endemic situation
in terms of T. solium infection. Several preclinical trial studies
have been taking place to ensure the efficacy of niclosamide for the
treatment of other infections such as methicillin-resistant
Staphylococcus aureus and Zika virus. The drug is also used for
veterinary purposes.
View
Report Preview:
Unmet
medical needs in the field of Zika treatment and focus on reducing
tapeworm infections present significant opportunities for the global
niclosamide market. Increasing collaborations among major market
players and research institutes to study different treatment regimens
using niclosamide drive the market as well. However, the rising
number of regional/local generic entrants in the treatment of worm
infection is expected to lead to the fragmentation of the global
niclosamide market. Adoption of better health care facilities,
awareness regarding treatment of worm infections, and government
initiatives for proper hygiene and cleanliness are likely to propel
the market in developing countries.
The
global niclosamide market has been divided on the basis of product
type into the following segments: 95% niclosamide, 96%–98%
niclosamide, and 99% niclosamide. Based on application, the market
has been bifurcated into the human use and animal use categories. In
terms of dosage form, the market is classified into the following
groups: tablets, suspension, and others, of which tablets are
projected to hold a significant market share owing to factors such as
ease of drug administration, simplicity in manufacturing, and better
overall medicinal stability. By end-user, the global niclosamide
market is split into the following divisions: hospitals, specialty
clinics, veterinary clinics, and others.
Geographically,
the market is distributed over five regions: North America, Europe,
Asia Pacific, Latin America, and Middle East & Africa. The market
in Asia Pacific is projected to exhibit a high growth rate due to the
widespread incidence of tapeworm infections, growing awareness about
better health care facilities, and the significant number of regional
/ local manufacturers in the region. North America is predicted to
dominate the global niclosamide market due to the high cost of
therapy, substantial research initiatives for the efficacy studies of
niclosamide for the treatment of different targets, and the high per
capita health expenditure.
Several
generic entrants are entering the market. Significant penetration of
regional players owing to their wide network of distribution channels
and affordable pricing is the trend observed in the global
niclosamide market. Ongoing research for the product’s efficacy
testing for diverse pathogenic targets is estimated to provide
treatment opportunities for other viral infections, thereby steering
the market. The prevalence of T. solium is greater in low and middle
income countries. Therefore, rising demand for affordable medicines
is likely to drive the global niclosamide market, besides the
availability of other advanced treatment options or therapeutics for
the same infections.
Key
players in the global niclosamide market include Bayer AG, Taj
Pharmaceuticals Limited., D. H. Organics, Shaanxi Hanjiang
Pharmaceutical Group Co., Ltd., Prudence Pharma Chem, FULLLONGCHEM
CORP, Hubei Prosperity Galaxy Chemical Co., Ltd., and Inner Mongolia
Huatian Pharmaceutical Co., Ltd.
Request
to view Sample Report:
The
report offers a comprehensive evaluation of the market. It does so
via in-depth qualitative insights, historical data, and verifiable
projections about market size. The projections featured in the report
have been derived using proven research methodologies and
assumptions. By doing so, the research report serves as a repository
of analysis and information for every facet of the market, including
but not limited to: Regional markets, technology, types, and
applications.
No comments:
Post a Comment